Disorders of calcium homeostasis

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 17, Issue 4, 2003, Pages 529-546

  Carmeliet, Geert ^a   Van Cromphaut, Sophie ^a   Daci, Evis ^a   Maes, Christa ^a   Bouillon, Roger ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Calcium homeostasis; Parathyroid hormone; Parathyroid hormone related peptide; Vitamin D

Indexed keywords

ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCILYTIC AGENT; CALCITONIN; CALCITRIOL; CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM DERIVATIVE; CALCIUM SENSING RECEPTOR; FUROSEMIDE; GALLIUM NITRATE; GLUCOCORTICOID; GUANINE NUCLEOTIDE; HORMONE RECEPTOR BLOCKING AGENT; MITHRAMYCIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR ANTAGONIST; PARATHYROID HORMONE RELATED PROTEIN; SODIUM; UNCLASSIFIED DRUG; VITAMIN D; CALCIMIMETIC AGENT; PHOSPHONIC ACID DERIVATIVE; PROTEIN INHIBITOR; VITAMIN D DERIVATIVE;

ANTIBODY RESPONSE; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CALCIUM INTAKE; CALCIUM METABOLISM; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; FEEDBACK SYSTEM; GENE MUTATION; GRANULOMATOSIS; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOPARATHYROIDISM; MALIGNANT NEOPLASTIC DISEASE; MINERAL BALANCE; MOLECULAR INTERACTION; MOUSE STRAIN; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROID CARCINOMA; PARATHYROID DISEASE; PARATHYROID HORMONE RELEASE; PARATHYROIDECTOMY; PATHOPHYSIOLOGY; PREVENTIVE MEDICINE; PRIMARY HYPERPARATHYROIDISM; PROTEIN FUNCTION; PROTEIN TARGETING; PSEUDOHYPOPARATHYROIDISM; REVIEW; SARCOIDOSIS; SECONDARY HYPERPARATHYROIDISM; TREATMENT PLANNING; VITAMIN D DEFICIENCY; VITAMIN D INTOXICATION; VITAMIN D METABOLISM; VITAMIN D RESISTANT RICKETS; VITAMIN SUPPLEMENTATION; CALCIUM CELL LEVEL; CELL FUNCTION; HORMONE SYNTHESIS; VITAMIN INTAKE;

EID: 0345171002     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2003.08.001     Document Type: Review

References (70)

1. Brown EM, Gamba G, Riccardi D et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993; 366: 575-580.
2. Brown EM. Physiology and pathophysiology of the extracellular calcium-sensing receptor. American Journal of Medicine 1999; 106: 238-253.
3. Riccardi D, Hall AE, Chattopadhyay N et al. Localization of extracellular Ca2+/polyvalent cation-sensing protein in kidney. American Journal of Physiology (Renal Physiology) 1998; 274: F611-F622.
4. Brown AM & McLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiological Reviews 2001; 81: 240-297.
5. Pearce S. Extracellular 'calcistat' in health and disease. Lancet 1999; 353: 82-83.
6. Pollak MR, Brown EM, Chou Y-HW et al. Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993; 75: 1297-1303.
7. Auwerx J, Demedts M & Bouillon R. Altered parathyroid set point to calcium in familial hypocalciuric hypercalcaemia. Acta Endocrinologica 1984; 106: 215-218.
8. Pollak MR, Brown EM, Estep HL et al. Autosomal dominant hypocalcaemia caused by a Ca2+-sensing receptor gene mutation. Nature Genetics 1994; 8: 303-307.
9. Kifor O, Moore FD, Wang P et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 1996; 81: 1598-1606.
10. Autry CP, Kifor O, Brown EM et al. Ca2+ receptor mRNA and protein increase in the rat parathyroid gland with advancing age. Journal of Endocrinology 1997; 153: 437-444.
11. Ho C, Connor DA, Pollak MR et al. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nature Genetics 1995; 11: 389-394.
12. Kos CH, Karaplis AC, Peng JB et al. The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. Journal of Clinical Investigation 2003; 111: 1021-1028.
13. Tu Q, Pi M, Karsenty G et al. Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. Journal of Clinical Investigation 2003; 111: 1029-1037.
14. Goodman WG. Calcimimetic agents for the treatment of hyperparathyroidism. Current Opinion in Nephrology and Hypertension 2001; 10: 575-580.
15. Nemeth EF. Receptor antagonists. The search for calcium receptor antagonists (calcilytics). Journal of Molecular Endocrinology 2002; 29: 15-21.
16. Juppner HW, Gardella TJ, Brown EM, et al. Parathyroid hormone and parathyroid hormone-related peptide in the regulation of calcium homeostasis and bone development. In DeGroot LJ & Jameson JL (eds) Endocrinology, 4th edn. Philadelphia: W.B. Saunders Company, 2001, pp 969-998.
17. Mannstadt M, Juppner H & Gardella TJ. Receptors for PTH and PTHrP: Their biological importance and functional properties. American Journal of Physiology (Renal Physiology) 1999; 277: F665-F675.
18. Schipani E, Kruse K & Juppner H. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 1995; 268: 98-100.
19. Jobert AS, Zhang P, Couvineau A et al. Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia. Journal of Clinical Investigation 1998; 102: 34-40.
20. Bilezikian JP, Potts Jr JT, Fuleihan GE-H et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: A perspective for the 21st century. Journal of Bone and Mineral Research 2002; 17: N2-N11.
21. Agarwal SK, Guru SC, Heppner C et al. Menin interacts with the API transcription factor JunD and represses JunD-activated transcription. Cell 1999; 96: 143-152.
22. Thakker RV & Juppner H. Genetic disorders of calcium homeostasis caused by abnormal regulation of parathyroid hormone secretion or responsiveness. In DeGroot LJ & Jameson JL (eds) Endocrinology, 4th edn. Philadelphia: W.B. Saunders Company, 2001, pp 1062-1074.
23. Mulligan LM, Eng C, Healey CS et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genetics 1994; 6: 70-74.
24. Cryns VL, Thor A, Xu HJ et al. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. New England Journal of Medicine 1994; 330: 757-761.
25. Silver J, Kilav R, Sela-Brown A et al. Molecular mechanisms of secondary hyperparathyroidism. Pediatric Nephrology 2000; 14: 626-628.
26. Fukagawa M, Kazama JJ & Kurokawa K. Renal osteodystrophy and secondary hyperparathyroidism. Nephrology, Dialysis, Transplantation 2002; 17 (supplement 10): 2-5.
27. Kumar PG, Laloraya M, Wang CY et al. The autoimmune regulator (AIRE) is a DNA-binding protein. Journal of Biological Chemistry 2001; 276: 41 357-41 364.
28. Ramsey C, Winqvist O, Puhakka L et al. Aire deficient mice develop multiple features of APECED phenotype and show altered immune response. Human Molecular Genetics 2002; 11: 397-409.
29. Karaplis AC, Lim SK, Baba H et al. Inefficient membrane targeting, translocation, and proteolytic processing by signal peptidase of a mutant preproparathyroid hormone protein. Journal of Biological Chemistry 1995; 270: 1629-1635.
30. Weinstein LS, Yu S, Warner DR & Liu J. Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocrine Reviews 2001; 22: 675-705.
31. Liu J, Litman D, Rosenberg MJ et al. A GNASI imprinting defect in pseudohypoparthyroidism type 1B. Journal of Clinical Investigation 2000; 106: 1167-1174.
32. Levine MA. Hypoparathyroidism and pseudohypoparathyroidism. In DeGroot LJ & Jameson JL (eds) Endocrinology, 4th edn. Philadelphia: W.B. Saunders Company, 2001, pp 1133-1153.
33. Haussler MR, Whitfield GK, Haussler CA et al. The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed. Journal of Bone and Mineral Research 1998; 13: 325-349.
34. Zehnder D, Bland R, Williams MC et al. Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. Journal of Clinical Endocrinology and Metabolism 2001; 86: 888-894.
35. Kato S, Yanagisawa J, Murayama A et al. The importance of 25-hydroxyvitamin D3 1 alpha-hydroxylase gene in vitamin D-dependent rickets. Current Opinion in Nephrology and Hypertension 1998; 7: 377-383.
36. Balsan S, Garabedian M, Larchet M et al. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D. Journal of Clinical Investigation 1986; 77: 1661-1667.
37. Hochberg Z, Tiosano D & Even L. Calcium therapy for calcitriol-resistant rickets. Journal of Pediatrics 1992; 121: 803-808.
38. Yoshizawa T, Handa Y, Uematsu Y et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nature Genetics 1997; 16: 391-396.
39. Li YC, Pirro AE, Amling M et al. Targeted ablation of the vitamin D receptor: An animal model of vitamin D-dependent rickets type II with alopecia. Proceedings of the National Academy of Sciences of the USA 1997; 94: 9831-9835.
40. Van Cromphaut SJ, Dewerchin M, Hoenderop JG et al. Duodenal calcium absorption in vitamin D receptor-knockout mice: Functional and molecular aspects. Proceedings of the National Academy of Sciences of the USA 2001; 98: 13 324-13 329.
41. Erben RG, Soegiarto DW, Weber K et al. Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and non genomic functions of vitamin D. Molecular Endocrinology 2002; 16: 1524-1537.
42. Murayama A, Takeyama K, Kitanaka S et al. The promoter of the human 25-hydroxyvitamin D3 1 alpha-hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1 alpha, 25(OH)2D3. Biochemical and Biophysical Research Communications 1998; 249: 11-16.
43. Wasserman RH. Vitamin D and the intestinal absorption of calcium and phosphorus. In Feldman D, Glorieux FH & Pike JW (eds) Vitamin D. San Diego: Academic Press, 1997, pp 259-273.
44. Amling M, Priemel M, Holzmann T et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: Formal histomorphometric and biomechanical analyses. Endocrinology 1999; 140: 4982-4987.
45. Li YC, Bolt MJ, Cao LP & Sitrin MD. Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism. American Journal of Physiology (Endocrinology and Metabolism) 2001; 281: E558-E564.
46. Li YC, Pirro AE & Demay MB. Analysis of vitamin D-dependent calcium-binding protein messenger ribonucleic acid expression in mice lacking the vitamin D receptor. Endocrinology 1998; 139: 847-851.
47. Dardenne O, Prud'homme J, Arabian A et al. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates in animal model of pseudovitamin D-deficiency rickets. Endocrinology 2001; 142: 3135-3141.
48. Panda DK, Miao D, Tremblay ML et al. Targeted ablation of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme: Evidence for skeletal, reproductive, and immune dysfunction. Proceedings of the National Academy of Sciences of the USA 2001; 98: 7498-7503.
49. 3: Biochemical, histomorphometric, and biomechanical analyses. Journal of Bone and Mineral Research 2003; 18: 637-644.
50. Dardenne O, Prud'homme J, Hacking SA et al. Correction of the abnormal mineral ion homeostasis with a high-calcium, high-phosphorus, high-lactose diet rescues the PDDR phenotype of mice deficient for the 25-hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1). Bone 2003; 32: 332-340.
51. Van Abel M, Hoenderop JG, Van Der Kemp AW et al. Regulation of the epithelial Ca2+ channels in small intestine as studied by quantitative mRNA detection. American Journal of Physiology (Gastrointestinal and Liver Physiology) 2003; 285: G78-G85.
52. Hoenderop JG, Dardenne O, Van Abel M et al. Modulation of renal Ca2+ transport protein genes by dietary Ca2+ and 1,25-dihydroxyvitamin D3 in 25-hydroxyvitamin D3-1alpha-hydroxylase knockout mice. FASEB Journal 2002; 16: 1398-1406.
53. Stewart AF & Broadus AE. Malignancy-associated hypercalcemia. In DeGroot LJ & Jameson JL (eds) Endocrinology, 4th edn. Philadelphia: W.B. Saunders Company, 2001, pp 1093-1100.
54. Bayne MC & Illidge TM. Hypercalcaemia, parathyroid hormone-related protein and malignancy. Clinical Oncology 2001; 13: 372-377.
55. Wysolmerski JJ & Broadus AE. Hypercalcemia of malignancy: The central role of parathyroid hormone-related protein. Annual Review of Medicine 1994; 45: 189-200.
56. Kukreja SC, Shevrin DH, Wimbiscus SA et al. Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors. Journal of Clinical Investigation 1988; 82: 1798-1802.
57. Taube T, Elomaa I, Blomqvist C et al. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 1994; 15: 161-166.
58. Guise TA & Mundy GR. Cancer and bone. Endocrine Reviews 1998; 19: 18-54.
59. Linforth R, Anderson N, Hoey R et al. Coexpression of parathyroid hormone related protein and its receptor in early breast cancer predicts poor patient survival. Clinical Cancer Research 2002; 8: 3172-3177.
60. Guise TA, Yin JJ, Taylor SD et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. Journal of Clinical Investigation 1996; 98: 1544-1549.
61. Guise TA, Yin JJ, Thomas RJ et al. Parathyroid hormone-related protein (PTHrP)-(I-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone 2002; 30: 670-676.
62. Wysolmerski JJ, Dann PR, Zelazny E et al. Overexpression of parathyroid hormone-related protein causes hypercalcemia but not bone metastases in a murine model of mammary tumorigenesis. Journal of Bone and Mineral Research 2002; 17: 1164-1170.
63. Grill V, Ho P, Body JJ et al. Parathyroid hormone-related protein: Elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. Journal of Clinical Endocrinology and Metabolism 1991; 73: 1309-1315.
64. Strewler GJ. The parathyroid hormone-related protein. Endocrinology and Metabolism Clinics of North America 2000; 29: 629-645.
65. Massfelder T & Helwig JJ. The parathyroid hormone-related protein system: More data but more unsolved questions. Current Opinion in Nephrology and Hypertension 2003; 12: 35-42.
66. Karaplis AC, Luz A, Glowacki J et al. Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes and Development 1994; 8: 277-289.
67. Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Seminars in Oncology 2002; 29: 12-18.
68. Diel IJ, Solomayer EF & Bastert G. Bisphosphonates and the prevention of metastasis: First evidences from preclinical and clinical studies. Cancer 2000; 88: 3080-3088.
69. Hortobagyi GN. Novel approaches to the management of bone metastases in patients with breast cancer. Seminars in Oncology 2002; 29: 134-144.
70. Gallwitz WE, Guise TA & Mundy GR. Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. Journal of Clinical Investigation 2002; 110: 1559-1572.